tradingkey.logo

Park Ha Biological Technology Co Ltd

PHH
0.385USD
0.000
收盘 12/19, 16:00美东报价延迟15分钟
11.31M总市值
--市盈率 TTM

Park Ha Biological Technology Co Ltd

0.385
0.000

关于 Park Ha Biological Technology Co Ltd 公司

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market.

Park Ha Biological Technology Co Ltd简介

公司代码PHH
公司名称Park Ha Biological Technology Co Ltd
上市日期Dec 27, 2024
CEOZhang (Xiaoqiu)
员工数量31
证券类型Ordinary Share
年结日Dec 27
公司地址- -
城市- -
上市交易所NASDAQ Capital Market Consolidated
国家- -
邮编- -
电话- -
网址- -
公司代码PHH
上市日期Dec 27, 2024
CEOZhang (Xiaoqiu)

Park Ha Biological Technology Co Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Xiaoqiu Zhang
Ms. Xiaoqiu Zhang
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Xiaoyan Zhu
Ms. Xiaoyan Zhu
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Xinyu Li
Ms. Xinyu Li
Chief Technology Officer, Product Manager
Chief Technology Officer, Product Manager
--
--
Ms. Li Wang
Ms. Li Wang
Director
Director
--
--
Ms. Yanan Shan
Ms. Yanan Shan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Qixiong Sheng
Mr. Qixiong Sheng
Independent Director
Independent Director
--
--
Mr. Xiaozhong Yu
Mr. Xiaozhong Yu
Independent Director Nominee
Independent Director Nominee
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Xiaoqiu Zhang
Ms. Xiaoqiu Zhang
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Xiaoyan Zhu
Ms. Xiaoyan Zhu
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Xinyu Li
Ms. Xinyu Li
Chief Technology Officer, Product Manager
Chief Technology Officer, Product Manager
--
--
Ms. Li Wang
Ms. Li Wang
Director
Director
--
--
Ms. Yanan Shan
Ms. Yanan Shan
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Qixiong Sheng
Mr. Qixiong Sheng
Independent Director
Independent Director
--
--

收入明细

FY2024
FY2023
FY2022
FY2021
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
China (Mainland)
2.38M
0.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Xiaoqiu Holding Ltd
56.24%
Changxin International Ltd Partnership
7.38%
XTX Markets LLC
0.13%
Two Sigma Investments, LP
0.08%
Ground Swell Capital, LLC
0.06%
其他
36.11%
持股股东
持股股东
占比
Xiaoqiu Holding Ltd
56.24%
Changxin International Ltd Partnership
7.38%
XTX Markets LLC
0.13%
Two Sigma Investments, LP
0.08%
Ground Swell Capital, LLC
0.06%
其他
36.11%
股东类型
持股股东
占比
Corporation
63.62%
Venture Capital
0.13%
Investment Advisor
0.08%
Hedge Fund
0.08%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
其他
36.03%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
15
103.15K
0.30%
+40.70K
2025Q2
9
21.62M
81.98%
-25.58K
2025Q1
8
21.60M
81.90%
-29.47K
2024Q4
6
21.63M
82.55%
+21.63M

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Xiaoqiu Holding Ltd
19.05M
56.24%
--
--
Feb 24, 2025
Changxin International Ltd Partnership
2.50M
7.38%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
16.85K
0.05%
+69.00
+0.41%
Jun 30, 2025
Morgan Stanley & Co. LLC
7.03K
0.02%
+7.03K
--
Jun 30, 2025
UBS Financial Services, Inc.
1.47K
0%
+1.47K
--
Jun 30, 2025
Morgan Stanley Smith Barney LLC
294.00
0%
+294.00
--
Jun 30, 2025
RBC Capital Markets Wealth Management
19.00
0%
-2.24K
-99.16%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Golden Dragon China ETF
0%
Invesco Golden Dragon China ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Park Ha Biological Technology Co Ltd的前五大股东是谁?

Park Ha Biological Technology Co Ltd 的前五大股东如下:
Xiaoqiu Holding Ltd持有股份:19.05M,占总股份比例:56.24%。
Changxin International Ltd Partnership持有股份:2.50M,占总股份比例:7.38%。
Geode Capital Management, L.L.C.持有股份:16.85K,占总股份比例:0.05%。
Morgan Stanley & Co. LLC持有股份:7.03K,占总股份比例:0.02%。
UBS Financial Services, Inc.持有股份:1.47K,占总股份比例:0.00%。

Park Ha Biological Technology Co Ltd的前三大股东类型是什么?

Park Ha Biological Technology Co Ltd 的前三大股东类型分别是:
Xiaoqiu Holding Ltd
Changxin International Ltd Partnership
XTX Markets LLC

有多少机构持有Park Ha Biological Technology Co Ltd(PHH)的股份?

截至2025Q3,共有15家机构持有Park Ha Biological Technology Co Ltd的股份,合计持有的股份价值约为103.15K,占公司总股份的0.30%。与2025Q2相比,机构持股有所增加,增幅为-81.67%。

哪个业务部门对Park Ha Biological Technology Co Ltd的收入贡献最大?

在FY2024,--业务部门对Park Ha Biological Technology Co Ltd的收入贡献最大,创收--,占总收入的--%。
KeyAI